Author

Shoko Inatani

Institution: Taisho Pharmaceutical (Japan)

Observed institution: Taisho Pharmaceutical (Japan)

ORCID: 0000-0001-7957-715X

Observed ORCID: 0000-0001-7957-715X

OpenAlex ID: A5067002906

Discovery of Novel Pyrazolylpyridine Derivatives for 20-Hydroxyeicosatetraenoic Acid Synthase Inhibitors with Selective CYP4A11/4F2 Inhibition

2022 · Madoka Kawamura, Yohei Kobashi, et al. · Journal of Medicinal Chemistry · 9

Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants

2020 · Ippei Yoshida, Kaho Arikawa, et al. · Antimicrobial Agents and Chemotherapy · 8

Prediction of a clinically effective dose of THY1773, a novel V1Breceptor antagonist, based on preclinical data

2021 · Shoko Inatani, Akiko Mizuno‐Yasuhira, et al. · Biopharmaceutics & Drug Disposition · 7

Preclinical Metabolism and Disposition of TP0473292, a Novel Oral Prodrug of the Potent Metabotropic Glutamate 2/3 Receptor Antagonist TP0178894 for the Treatment of Depression

2023 · Shoko Inatani, Motoki Ochi, et al. · Drug Metabolism and Disposition · 6

Renoprotective Effect of TP0472993, a Novel and Selective 20-Hydroxyeicosatetraenoic Acid Synthesis Inhibitor, in Mouse Models of Renal Fibrosis

2023 · Takashi Hirata, Hiroki Ohara, et al. · Journal of Pharmacology and Experimental Therapeutics · 4

Introduction of a carboxylic acid group into pyrazolylpyridine derivatives increased selectivity for inhibition of the 20-HETE synthase CYP4A11/4F2

2023 · Madoka Kawamura, Yohei Kobashi, et al. · Bioorganic & Medicinal Chemistry

Works count: 6

Citation count: 34

H-index: 4

I10-index: